ArticleAnnals of translational medicine2023
Sacituzumab Govitecan in HR-positive HER2-negative metastatic breast cancer.
Simone Nardin et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
3 papers cite it
this paperpooled itcites it